Welcome to our dedicated page for Joint SEC filings (Ticker: JYNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Joint Corp. (NASDAQ: JYNT) files a range of reports and disclosures with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a national operator, manager and franchisor of chiropractic clinics. These SEC filings cover its Franchise Operations segment, refranchising activity, regional developer arrangements, credit facilities and stock repurchase programs, among other topics relevant to shareholders and analysts.
On this page, you can review The Joint Corp.’s key filings, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss its retail healthcare business model, classification as a lessor of nonfinancial intangible assets, and the performance of its franchised and company-owned or managed clinics. Current reports on Form 8-K provide timely disclosure of material events, such as asset purchase agreements to sell groups of clinics to franchisees, the acquisition or modification of regional developer rights, amendments to its revolving credit agreement, and board authorizations for additional stock repurchase capacity.
Filings also address accounting and reporting matters, including restatements of previously issued financial statements and related internal control considerations, as well as separation agreements with certain officers. Together, these documents outline how The Joint Corp. structures its franchise and management arrangements, manages its balance sheet and capital allocation, and responds to regulatory and governance requirements.
Stock Titan enhances access to these disclosures with real-time updates from the SEC’s EDGAR system and AI-powered summaries that explain the significance of complex filings. Users can quickly identify information related to refranchising transactions, development rights, credit facility amendments and other material events affecting JYNT, without reading every line of each report.
The Joint Corp. has signed and begun executing an Asset Purchase Agreement to sell 45 company-owned or managed clinics in Southern California to Elite Chiro Group for approximately $2.3 million. On April 27, 2026, ownership of 13 clinics transferred, while Elite Chiro Group assumed operations of the remaining 32 clinics under a Management Service Agreement until lease assignments are completed.
Upon completion of this transaction and two previously announced refranchising agreements, the company expects to operate only three corporate-managed clinics out of 960 locations, effectively shifting to a capital-light, pure-play franchisor model focused on supporting franchisee growth.
The Joint Corp. signed an Asset Purchase Agreement to sell the assets of, and grant franchise rights for, 45 company-owned or managed clinics in Southern California to Elite Chiro Group for an aggregate purchase price of $2.3 million, subject to adjustments.
The price includes prorated franchise fees across 45 new franchise agreements and non-exclusive development rights for 10 additional clinics in agreed metropolitan areas. Elite Chiro Group will pay a non-refundable $150,000 down payment for exclusivity, with the remaining amount placed in escrow and released as each clinic closes. Each clinic closing depends on assignment of its existing lease and other customary closing conditions.
JOINT Corp filed Amendment No. 3 to a Schedule 13G/A reporting Charles E. Jobson's beneficial ownership of 11.4% of the company's Common stock, equal to 1,645,803 shares.
The filing lists Mr. Jobson with sole voting and sole dispositive power over 1,645,803 shares. The filing shows CUSIP 47973J102 and is signed on 04/23/2026.
JOINT Corp disclosed that 10% owner Charles E. Jobson made an open-market purchase of common stock. On April 21, 2026, he bought 509 shares at $8.58 per share. Following this transaction, he directly holds 1,645,803 common shares of JOINT Corp.
The Joint Corp. is asking stockholders to vote at its virtual 2026 annual meeting while highlighting a return to profitability and a shift to a pure-play franchisor model. The proxy outlines seven director nominees, advisory votes on executive pay and its frequency, and auditor ratification.
In 2025, consolidated revenue reached $54.9 million, up from $52.2 million, with net income of $2.9 million compared to a $5.8 million loss in 2024. Consolidated Adjusted EBITDA rose to $13.0 million and system-wide sales were $532.4 million, a 0.4% increase.
The company refranchised 41 clinics, signed agreements covering 22 more, and closed nine, ending 2025 with 960 clinics, of which 885 were franchised. It repurchased 1.3 million shares for $11.3 million and generated $1.8 million of operating cash flow, while projecting higher-margin, asset-light economics once refranchising is completed.
The Vanguard Group filed Amendment No. 3 to a Schedule 13G for Joint Corp/The reporting that, after an internal realignment, its filing shows 0 shares beneficially owned and 0% of the class. The amendment cites the January 12, 2026 realignment and SEC Release No. 34-39538 to explain that certain Vanguard subsidiaries will report ownership separately.
The filing lists the issuer as Joint Corp/The (principal executive offices at 16767 N Perimeter Dr, Suite 110, Scottsdale, AZ) and is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.
Bandera Partners and affiliated investors updated their ownership disclosure in The Joint Corp. They may be deemed to beneficially own 3,937,296 shares of common stock, representing about 27.9% of the company based on 14,114,334 shares outstanding as of March 9, 2026.
The higher ownership percentage results solely from a decrease in total shares outstanding, not from new purchases or sales. The filing states that no reporting person has traded The Joint Corp. securities in the past 60 days.
The Joint Corp. files its Annual Report describing a large, highly franchised chiropractic network and a shift toward a pure-play franchisor model. The company operated 960 clinics in 43 states as of December 31, 2025 and delivered over 14.4 million patient visits in 2025.
System-wide sales reached $532.4 million in 2025, up sharply from $22.3 million in 2012, while 2025 same-store sales were flat in percentage terms. The Joint emphasizes a cash-based, non-insurance model with average adjustment prices around $37, about 51% below industry averages, and collects a 7% royalty and 2% marketing fee from franchisees.
Management highlights continued growth through franchise sales, opening clinics already in development, and refranchising all company-owned or managed clinics, supported by an experienced leadership team. Key risks include nationwide labor shortages, inflation-driven wage pressure, tighter credit, and evolving privacy, cybersecurity and state-level corporate practice regulations.
The Joint Corp. reported a return to profitability for 2025 while accelerating its shift to a franchisor model. Full-year revenue rose to $54.9 million from $52.2 million, with consolidated net income improving to $2.9 million from a loss of $5.8 million. Consolidated Adjusted EBITDA increased 13.9% to $13.0 million.
In the fourth quarter, revenue grew 3.1% to $15.2 million and net income reached $1.0 million. System-wide sales for 2025 were $532.4 million, though comp sales declined 0.4%. The company refranchised 41 clinics, ended the year with 960 locations, and repurchased 1.3 million shares for $11.3 million.
For 2026, guidance calls for system-wide sales between $519 million and $552 million, system-wide comp sales between (3)% and 3%, consolidated Adjusted EBITDA of $12.5–$13.5 million, and 30–35 new franchised clinic openings as it completes its transition to a capital-light, pure-play franchisor model.
Bowman Scott Justin reported acquisition or exercise transactions in this Form 4 filing.
JOINT Corp disclosed that Chief Financial Officer Scott Justin Bowman received a grant of 28,301 shares of common stock as a stock award. These shares are restricted, with 25% scheduled to vest on each of the first four anniversaries of the grant date. Following this award, Bowman directly holds 48,285 common shares.